Log in

NASDAQ:SYNSynthetic Biologics Stock Price, Forecast & News

$0.54
+0.03 (+5.50 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.51
Now: $0.54
$0.54
50-Day Range
$0.32
MA: $0.44
$0.57
52-Week Range
$0.25
Now: $0.54
$0.64
Volume92,400 shs
Average Volume376,669 shs
Market Capitalization$9.88 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYN
CUSIPN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$9.88 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

Synthetic Biologics (NASDAQ:SYN) Frequently Asked Questions

How has Synthetic Biologics' stock been impacted by COVID-19 (Coronavirus)?

Synthetic Biologics' stock was trading at $0.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SYN stock has increased by 50.3% and is now trading at $0.5412. View which stocks have been most impacted by Coronavirus.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Synthetic Biologics.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics, Inc (NASDAQ:SYN) posted its earnings results on Tuesday, May, 5th. The company reported ($0.20) EPS for the quarter. View Synthetic Biologics' earnings history.

Has Synthetic Biologics been receiving favorable news coverage?

Headlines about SYN stock have been trending negative recently, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Synthetic Biologics earned a news impact score of -2.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Synthetic Biologics.

Who are some of Synthetic Biologics' key competitors?

What other stocks do shareholders of Synthetic Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synthetic Biologics investors own include Crispr Therapeutics (CRSP), Amarin (AMRN), Vaxart (VXRT), Agile Therapeutics (AGRX), Armata Pharmaceuticals (ARMP), Altimmune (ALT), Advanced Micro Devices (AMD), Nabriva Therapeutics (NBRV), vTv Therapeutics (VTVT) and Aytu Bioscience (AYTU).

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the following people:
  • Mr. Steven A. Shallcross, Interim CEO, CFO, Sec., Treasurer & Sec. (Age 57)
  • Dr. Joseph A. Sliman, Chief Medical Officer (Age 45)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Michael Kaleko M.D., Ph.D., Sr. VP of R&D
  • Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the NASDAQ under the ticker symbol "SYN."

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.54.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $9.88 million.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is www.syntheticbiologics.com.

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.